Can I read Cost-Effectiveness of SGLT2 & GLP-1 in Diabetes on EtoBox?

Cost-Effectiveness of SGLT2 & GLP-1 in Diabetes by Melanie Michelle Miranda Valencia is a document available to read on EtoBox.

What is Cost-Effectiveness of SGLT2 & GLP-1 in Diabetes about?

A study evaluated the lifetime cost-effectiveness of using SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy for type 2 diabetes compared to metformin. While these newer therapies showed lower rates of cardiovascular complications, they were not cost-effective, requiring a 70% reduction in costs to be viable. The findings support current recommendations to limit their use to patients with high cardiovascular risk or established conditions.

Author

Melanie Michelle Miranda Valencia

Language

EN